CBUS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 35.8%, SMA50 66.56%, SMA200 102.9%). The stock’s 14-day RSI is 70.37 (overbought), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.37% below its high and over 222.94% above its low. Average 10-day trading volume of 939.35 thousand shares is significantly above the 3-month average of 373.15 thousand, indicating heightened recent market interest.

Cibus, Inc. generated EPS of -$3.22 over the past year. Five-year average earnings growth is 29.09%. Wall Street analysts project EPS growth of 50.54% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $15.00. The high target offers 610.23% upside. The low target suggests 326.14% downside. The mean target is $20.00. This offers 468.18% upside. Cibus, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 7.32%. The prior quarter beat by -11.59%. Over the last six quarters, Apple has recorded several small beats. These include -99.86% in August 08, 2024.

Cibus, Inc. has 52.54 million shares outstanding. The public float is 36.42 million shares, elevated short interest at 2.84% of float. This equals 1.25 million shares. The short ratio is 6.44 days. Institutional investors hold 43.63% of the float. Insiders own 33.53%. Gocal Gregory Francis William holds 314.84 thousand shares, Broos Carlo has 74.20 thousand shares and Prante Gerhard has 7.71 thousand shares.

Cibus, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.58. This means the shares are trading below this model’s fair value.

Cibus, Inc. (NASDAQ:CBUS) closed at $3.52 USD, losing -$0.21 (-5.63%) from the previous close of $3.73. The stock is currently mid-range between its 52-week high and low $1.09 and $3.80. With a market capitalization of about $185.60 million, Cibus, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.80). Key stats such as the average daily volume over the past year has been around 377.04 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Cibus, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Peter R. Beetham, the company employs approximately 157 people and listed since July 20, 2017. Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties.

Our AI price prediction model suggests that Cibus, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.35%, with price expected at $3.99 by March 11, 2026, within a range of $3.57 to $4.45 3-Month Outlook: Projected rise of 63.92%, reaching $5.77 by May 26, 2026, with a range of $5.14 to $6.09. 1-Year Outlook: Projected gain of 81.53%, with price at $6.39 by February 25, 2027, within a range of $1.38 to $5.65.

Cibus, Inc. (NASDAQ:CBUS) shares are flat -2.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cibus, Inc. trading at a premium to the broader market with a P/E of -1.56. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.21, suggesting 502.56% upside. Our AI forecast model points to short-term strength (13.35% over two weeks), a medium-term rise (63.92% over three months), and a longer-term gain (81.53% over one year), with expected trading ranges indicating moderate volatility.

Cibus, Inc. trades at a P/E ratio of -1.56, slightly below the S&P 500 average, with a price-to-sales ratio of 48.71 and a price-to-book ratio of 3.68 trading at moderately above to book value. The P/FCF stands at -3.57, also below market averages.